MGX Metagenomi Therapeutics, Inc.
Metagenomi Therapeutics, Inc. (MGX) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is a loss of $0.69 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +4.2% since its last earnings release on August 10, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Metagenomi Therapeutics, Inc.
Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif.
Sector
Healthcare
Industry
Biotechnology